Jorge Magallon, MD
Interventional Cardiology · San Antonio, TXNPI 1134154172
Payments from drug & device makers
Across 1,169 payments — averaging $40.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- Medtronic$9K
- Penumbra, Inc.$4K
- Angiodynamics, Inc.$3K
- Novartis$2K
- Actelion Pharmaceuticals US, Inc.$2K
- plus $17K from 52 others
What the payments were for
- Travel & lodging$10,11921%
- Food & beverage$37,17579%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$5,548
- Indigo System$4,195
- OPTIS$2,642
- Auryon Laser System 100-120 Vac$2,111
- Impella$1,143
- Mitra Clip system$1,067
- Xience V coronary stent system$1,060
- GENERAL VASCULAR ACCESS$878
- Edwards SAPIEN 3 Transcatheter Heart Valve$781
- Bashir Endovascular Catheter$533
- PRESSUREWIRE$507
- Diamondback Coronary$482
- BioMimics 3D Vascular Stent System$461
- Barostim Neo System$412
- NAVITOR$340
- COROFLOW$340
- Serrantor$275
- CoreValve Evolut$265
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$264
- FLOWTRIEVER CATHETER, S$225
How this compares
$47,293 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 61 | $759,748 |
| EntrestoSacubitril/Valsartan | 395 | $627,004 |
| EliquisApixaban | 421 | $549,161 |
| UptraviSelexipag | 18 | $460,288 |
| AdempasRiociguat | 16 | $232,488 |
| FarxigaDapagliflozin Propanediol | 173 | $223,531 |
| JardianceEmpagliflozin | 126 | $186,921 |
| LetairisAmbrisentan | 11 | $142,877 |
| XareltoRivaroxaban | 90 | $131,159 |
| Repatha SureclickEvolocumab | 61 | $75,223 |
| BrilintaTicagrelor | 68 | $71,404 |
| Tadalafil | 18 | $26,008 |
| VerquvoVericiguat | 16 | $25,313 |
| Repatha PushtronexEvolocumab | 12 | $17,978 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $11,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,914 | $1,220,03679 claims |
| NovartisEntresto | $2,432 | $627,004395 claims |
| PfizerEliquis | $436 | $549,161421 claims |
| AstraZenecaFarxiga, Brilinta | $176 | $294,935241 claims |
| BayerAdempas | $35 | $232,48816 claims |
| Boehringer IngelheimJardiance | $487 | $186,921126 claims |
| GileadLetairis | $56 | $142,87711 claims |
| Johnson & JohnsonXarelto | $1,523 | $131,15990 claims |
| MerckVerquvo | $741 | $25,31316 claims |
| Esperion Therapeutics, Inc.Nexlizet | $63 | $11,80812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in San Antonio
- Jorge AlvarezSan Antonio$1.6M
- Robert ChiltonSan Antonio$1.3M
- Marvin EngSan Antonio$756K
- Nandish ThukralSan Antonio$368K
- Anand PrasadSan Antonio$328K
- Jose PerezSan Antonio$312K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.